Join 60,000+ competitive exam aspirants
Under the Union Budget 2026тАУ27, the Government of India proposed the launch of which scheme aimed at developing India into a global biopharma manufacturing hub?
National Bioscience Acceleration Programme
Pharma Vision 2047
Biopharma SHAKTI
BioNex India Mission Question ID : 4410092008985 Option 1 ID : 4410097911217 Option 2 ID : 4410097911214 Option 3 ID : 4410097911216 Option 4 ID : 4410097911215 Status : Answered Chosen Option : D
Biopharma SHAKTI
Biopharma SHAKTI is a specialized government scheme introduced in the Union Budget 2026-27 to bolster India's domestic biopharmaceutical infrastructure. The initiative aims to provide R&D subsidies, regulatory support, and manufacturing incentives to transform the nation into a global hub for biologics and biosimilars.
Biotechnology leverages biological systems, living organisms, or derivatives thereof to make or modify products for specific use, governed by the principles of molecular biology and genetic engineering.
The relationship between R&D investment and output in biopharma is non-linear; higher capital infusion directly correlates with accelerated innovation and drug discovery timelines.
Biopharma SHAKTI is a specialized government scheme introduced in the Union Budget 2026-27 to bolster India's domestic biopharmaceutical infrastructure. The initiative aims to provide R&D subsidies, regulatory support, and manufacturing incentives to transform the nation into a global hub for biologics and biosimilars.
Think of Biopharma SHAKTI as an industrial-scale greenhouse program that provides the best sunlight, climate control, and nutrients, allowing the farmers (pharma companies) to grow rare medicinal plants much faster than they could on their own.
SHAKTI: Strategic Hub for Advancement in Knowledge, Technology, and Innovation.
C=VmтАЛ тАФ Represents concentration of active biopharmaceutical ingredients in a medium.
k=AeтИТRTEaтАЛтАЛ тАФ Arrhenius equation governing reaction rates in biochemical manufacturing processes.
Biopharmaceutical manufacturing relies on bioreactor optimization and downstream processing technologies. The principle involves scaling up cultivation of microbial or mammalian cells (using nutrient media under controlled pH and temperature conditions) to synthesize high-molecular-weight proteins like monoclonal antibodies, defined by the formula Yield=Biomass├ЧSpecific┬аProductivity├ЧTime.
Focuses on strengthening indigenous manufacturing of biosimilars and high-value biologics.
Aims to reduce import dependency for critical vaccines and life-saving medicines.
Provides incentives for integrating AI in protein folding research and drug discovery.
Reduces the cost of advanced treatments for chronic diseases.
Promotes self-reliance in the healthcare sector.
Encourages high-end skilled employment in biotech labs.
Requires massive initial capital expenditure for infrastructure.
Highly sensitive to global regulatory standards and intellectual property hurdles.
Large-scale production of monoclonal antibodies for cancer immunotherapy.
Development of recombinant DNA-based vaccines.
The biopharma industry is characterized by high entry barriers due to the complexity of protein synthesis.
Option D (BioNex) is a distractor often associated with generic biotech research, not the specific policy name in the budget.
C is correct тАФ Biopharma SHAKTI is the specific initiative proposed under the Union Budget 2026-27 to position India as a global manufacturing leader in biopharmaceuticals.
When analyzing government schemes, look for keywords like 'SHAKTI', 'Mission', or 'Acceleration' as these reflect current policy trends towards strategic autonomy in technology.